Unknown

Dataset Information

Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women.


ABSTRACT:

Background

Every 2 minutes, there is a pregnancy-related death worldwide, with one-third caused by severe postpartum hemorrhage. Although international trials demonstrated the efficacy of 1000 mg tranexamic acid in treating postpartum hemorrhage, to the best of our knowledge, there are no dose-finding studies of tranexamic acid on pregnant women for postpartum hemorrhage prevention.

Objective

This study aimed to determine the optimal tranexamic acid dose needed to prevent postpartum hemorrhage.

Study design

We enrolled 30 pregnant women undergoing scheduled cesarean delivery in an open-label, dose ranging study. Subjects were divided into 3 cohorts receiving 5, 10, or 15 mg/kg (maximum, 1000 mg) of intravenous tranexamic acid at umbilical cord clamping. The inclusion

SUBMITTER: Ahmadzia HK 

PROVIDER: S-EPMC8149481 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature